Evaluation of Factors Affecting Compliance With Disease-Modifying Treatments in Multiple Sclerosis Patients

Emine Rabia Koç; Furkan Sarıdaş; Ömer Faruk Turan

Makale detayları

Evaluation of Factors Affecting Compliance With Disease-Modifying Treatments in Multiple Sclerosis Patients

Yazarlar:

Emine Rabia Koç | Furkan Sarıdaş | Ömer Faruk Turan

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Nöroloji ve Nöromüsküler Hastalıklar

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.50 Issue 1, pp.1-4

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001317379

pISSN:

1300-414X

Anahtar kelimeler:

Özet:

 Multiple sclerosis is an acquired disabling neurological disease that affects approximately 2.3 million people worldwide, most commonly in young adults. Since MS is a chronic disease, patients need to use long-term treatment. Patients compliance with treatment is an issue that should be taken into consideration as a priority since it affects the course of the disease and long-term prognosis. Many factors affect treatment compliance. Identifying and correcting adverse factors affects treatment efficacy, safety, and disease outcomes. In this study, we aimed to evaluate the factors affecting the compliance of patients followed in an MS clinic to disease-modifying treatments. 209 MS patients were included in the study, and their age, gender, disease durations, education level, income, medication usage, and the administered way were recorded. The Morisky Medication Adherence Scale-8 MMAS-8 was applied to the patients with MS. The mean MMAS-8 score was 6.051.94. Treatment compliance was 31 low n66, 36.4 moderate n76, and 32.1 high n67. No difference was detected in terms of treatment compliance according to age, gender, disease duration, income level, disease-modifying treatments, and the type and administration way of these treatments p 0.074, 0.070, 0.600, 0.976, 0.940, 0.356, 0.249, 0.053, 0.701, respectively. In our study, age, education level, disease duration, treatment option, or route of administration did not affect compliance with disease-modifying treatment in MS patients. Our study results indicate that different factors affecting medication adherence in MS patients need to be explained.

 Multiple sclerosis is an acquired disabling neurological disease that affects approximately 2.3 million people worldwide, most commonly in young adults. Since MS is a chronic disease, patients need to use long-term treatment. Patients compliance with treatment is an issue that should be taken into consideration as a priority since it affects the course of the disease and long-term prognosis. Many factors affect treatment compliance. Identifying and correcting adverse factors affects treatment efficacy, safety, and disease outcomes. In this study, we aimed to evaluate the factors affecting the compliance of patients followed in an MS clinic to disease-modifying treatments. 209 MS patients were included in the study, and their age, gender, disease durations, education level, income, medication usage, and the administered way were recorded. The Morisky Medication Adherence Scale-8 MMAS-8 was applied to the patients with MS. The mean MMAS-8 score was 6.051.94. Treatment compliance was 31 low n66, 36.4 moderate n76, and 32.1 high n67. No difference was detected in terms of treatment compliance according to age, gender, disease duration, income level, disease-modifying treatments, and the type and administration way of these treatments p 0.074, 0.070, 0.600, 0.976, 0.940, 0.356, 0.249, 0.053, 0.701, respectively. In our study, age, education level, disease duration, treatment option, or route of administration did not affect compliance with disease-modifying treatment in MS patients. Our study results indicate that different factors affecting medication adherence in MS patients need to be explained.

 Multiple sclerosis is an acquired disabling neurological disease that affects approximately 2.3 million people worldwide, most commonly in young adults. Since MS is a chronic disease, patients need to use long-term treatment. Patients compliance with treatment is an issue that should be taken into consideration as a priority since it affects the course of the disease and long-term prognosis. Many factors affect treatment compliance. Identifying and correcting adverse factors affects treatment efficacy, safety, and disease outcomes. In this study, we aimed to evaluate the factors affecting the compliance of patients followed in an MS clinic to disease-modifying treatments. 209 MS patients were included in the study, and their age, gender, disease durations, education level, income, medication usage, and the administered way were recorded. The Morisky Medication Adherence Scale-8 MMAS-8 was applied to the patients with MS. The mean MMAS-8 score was 6.051.94. Treatment compliance was 31 low n66, 36.4 moderate n76, and 32.1 high n67. No difference was detected in terms of treatment compliance according to age, gender, disease duration, income level, disease-modifying treatments, and the type and administration way of these treatments p 0.074, 0.070, 0.600, 0.976, 0.940, 0.356, 0.249, 0.053, 0.701, respectively. In our study, age, education level, disease duration, treatment option, or route of administration did not affect compliance with disease-modifying treatment in MS patients. Our study results indicate that different factors affecting medication adherence in MS patients need to be explained.

 Multipl skleroz, dünya çapında yaklaşık 2,3 milyon insanı etkileyen, en sık genç yetişkinlerde görülen, edinilmiş sakatlığa yol açan nörolojik bir hastalıktır. MS kronik bir hastalık olduğundan hastaların uzun süreli tedavi kullanması gerekmektedir. Hastaların tedaviye uyumu hastalığın seyrini ve uzun dönem prognozu etkilediğinden öncelikli olarak dikkate alınması gereken bir konudur. Tedavi uyumunu etkileyen birçok faktör vardır. Olumsuz faktörlerin tespiti ve düzeltilmesi tedavi etkinlik ve güvenirlilik sonuçlarını ve hastalık sonlanımını etkiler. Bu çalışmada MS polikliniğinde takip edilen hastaların hastalık modifiye edici tedavilere uyumuna etki eden faktörlerin değerlendirilmesi planlanmıştır. Çalışmaya 209 MS hastası dahil edildi ve hastaların yaşı, cinsiyeti, hastalık süresi, eğitim düzeyi, geliri, ilaç kullanımı ve ilaç uygulanma şekli kaydedildi. MS hastalarına Morisky İlaç Uyum Ölçeği-8 MMAS-8 uygulandı. Ortalama MMAS-8 puanı 6,051,94 idi. Tedavi uyumu 31 düşük n66, 36,4 orta n76 ve 32,1 yüksek n67 idi. Yaş, cinsiyet, hastalık süresi, gelir düzeyi, hastalığı değiştirici tedaviler, bu tedavilerin türü ve uygulanma şekline göre tedaviye uyum açısından farklılık saptanmadı p 0,074, 0,070, 0,600, 0,976, 0,940, 0,356, 0,249, 0,053, 0,701. Çalışmamızda MS hastalarında yaş, eğitim düzeyi, hastalık süresi, tedavi seçeneği veya uygulama şeklinin hastalık değiştirici tedaviye uyumu etkilemediği görüldü. Çalışma sonuçlarımız MS hastalarında ilaç uyumunu etkileyen farklı faktörlerin açıklanması gerektiğini göstermektedir.

Makale detayları

Evaluation of Factors Affecting Compliance With Disease-Modifying Treatments in Multiple Sclerosis Patients

Yazarlar:

Emine Rabia Koç | Furkan Sarıdaş | Ömer Faruk Turan

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Nöroloji ve Nöromüsküler Hastalıklar

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.50 Issue 1, pp.1-4

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001317379

pISSN:

1300-414X

Multiple sclerosis

disease-modifying therapy

medication adharanceMultipl skleroz

hastalık modifiye edici tedavi

ilaç uyumu

Sayı

Makale detayları

Evaluation of Factors Affecting Compliance With Disease-Modifying Treatments in Multiple Sclerosis Patients

Yazarlar: Emine Rabia Koç | Furkan Sarıdaş | Ömer Faruk Turan

Yayıncı: Bursa Uludağ University

Ana Başlıklar: Nöroloji ve Nöromüsküler Hastalıklar

Dergi: Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.50 Issue 1, pp.1-4

Belge Tipi: Makale

Yayın Tarihi: 5/2024

Belge Dili: Türkçe

Document ID (Org No.): 2001317379

pISSN: 1300-414X

Multiple sclerosis

disease-modifying therapy

medication adharanceMultipl skleroz

hastalık modifiye edici tedavi

ilaç uyumu

Sayı

Yazarlar:

Emine Rabia Koç | Furkan Sarıdaş | Ömer Faruk Turan

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Nöroloji ve Nöromüsküler Hastalıklar

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.50 Issue 1, pp.1-4

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001317379

pISSN:

1300-414X